{"hands_on_practices": [{"introduction": "This practice explores the crucial difference between a test's intrinsic accuracy, defined by sensitivity and specificity, and its predictive value in a real-world population. Calculating the Positive Predictive Value ($PPV$) is a fundamental skill that grounds ethical counseling in statistical reality, helping patients understand what a positive screening result truly means. This exercise uses the common clinical scenario of Non-Invasive Prenatal Testing (NIPT) to demonstrate how low disease prevalence can dramatically affect a test's utility, a vital concept for providing ethical and effective patient care [@problem_id:5028518].", "problem": "A clinician is counseling a patient who has received a positive result for trisomy $21$ on Non-Invasive Prenatal Testing (NIPT). The test characteristics in the screened population are sensitivity $0.99$, specificity $0.999$, and the prevalence of trisomy $21$ is $0.001$. Using only fundamental definitions of sensitivity, specificity, prevalence, and conditional probability, derive an expression for the positive predictive value (PPV), which is the probability that the fetus actually has trisomy $21$ given a positive NIPT result. Then compute the PPV for these parameters. Express the PPV as a decimal (not with a percentage sign) and round your final numeric answer to four significant figures. Finally, briefly explain how this PPV should inform pre-test and post-test counseling in terms of autonomy, beneficence, and the need for confirmatory diagnostic testing.", "solution": "The problem as stated is scientifically grounded, well-posed, and objective. It presents a standard application of Bayesian statistics to evaluate the performance of a medical screening test. All necessary parameters (sensitivity, specificity, prevalence) are provided, and their values are realistic for the clinical context of Non-Invasive Prenatal Testing (NIPT) for trisomy $21$. The problem is therefore valid.\n\nWe begin by formally defining the events and probabilities involved.\nLet $D$ be the event that the fetus has trisomy $21$ (the \"disease\" is present).\nLet $D^c$ be the event that the fetus does not have trisomy $21$.\nLet $T^+$ be the event that the NIPT result is positive.\nLet $T^-$ be the event that the NIPT result is negative.\n\nFrom the problem statement, we are given the following values:\nThe prevalence of trisomy $21$ is the prior probability of the condition, $P(D) = 0.001$.\nThe sensitivity of the test is the probability of a positive result given that the disease is present, $P(T^+ | D) = 0.99$.\nThe specificity of the test is the probability of a negative result given that the disease is absent, $P(T^- | D^c) = 0.999$.\n\nWe are asked to derive an expression for the positive predictive value (PPV), which is defined as the probability that the fetus actually has trisomy $21$ given a positive test result. In probabilistic terms, this is the conditional probability $P(D | T^+)$.\n\nWe will use Bayes' theorem to find this value. The theorem states:\n$$\nP(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)}\n$$\nThe numerator contains terms that are directly given or can be derived immediately. We have $P(T^+ | D) = 0.99$ (sensitivity) and $P(D) = 0.001$ (prevalence).\n\nThe denominator, $P(T^+)$, is the total probability of receiving a positive test result. This can be calculated using the law of total probability, which involves marginalizing over the disease status:\n$$\nP(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)\n$$\nLet's analyze the terms in this expansion:\n$P(T^+ | D)$ is the sensitivity, given as $0.99$.\n$P(D)$ is the prevalence, given as $0.001$.\n$P(D^c)$ is the probability that the fetus does not have trisomy $21$. Since this is the complement of having the disease, $P(D^c) = 1 - P(D) = 1 - 0.001 = 0.999$.\n$P(T^+ | D^c)$ is the probability of a positive test in an unaffected fetus. This is the false positive rate. It is the complement of the specificity, since specificity, $P(T^- | D^c)$, is the probability of a true negative. Thus, $P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - \\text{specificity}$. In this case, $P(T^+ | D^c) = 1 - 0.999 = 0.001$.\n\nNow, let's substitute these terms into the formula for $P(T^+)$:\n$$\nP(T^+) = (0.99)(0.001) + (1 - 0.999)(1 - 0.001)\n$$\nSubstituting this expanded form of $P(T^+)$ back into the Bayes' theorem expression for PPV, we obtain the general formula for PPV in terms of sensitivity (sens), specificity (spec), and prevalence (prev):\n$$\n\\text{PPV} = P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)} = \\frac{(\\text{sens})(\\text{prev})}{(\\text{sens})(\\text{prev}) + (1 - \\text{spec})(1 - \\text{prev})}\n$$\nThis is the derived expression for the positive predictive value.\n\nNext, we compute the numerical value for the PPV using the given parameters:\n$\\text{sens} = 0.99$\n$\\text{spec} = 0.999$\n$\\text{prev} = 0.001$\n\nSubstituting these values into our derived formula:\n$$\n\\text{PPV} = \\frac{(0.99)(0.001)}{(0.99)(0.001) + (1 - 0.999)(1 - 0.001)}\n$$\n$$\n\\text{PPV} = \\frac{0.00099}{0.00099 + (0.001)(0.999)}\n$$\n$$\n\\text{PPV} = \\frac{0.00099}{0.00099 + 0.000999}\n$$\n$$\n\\text{PPV} = \\frac{0.00099}{0.001989}\n$$\n$$\n\\text{PPV} \\approx 0.497737556...\n$$\nThe problem requires the final numeric answer to be rounded to four significant figures.\n$$\n\\text{PPV} \\approx 0.4977\n$$\nThis result is profoundly important for clinical counseling. The calculated PPV of approximately $0.4977$ indicates that for a patient in this population who receives a positive NIPT result, there is only a $49.77\\%$ chance that the fetus actually has trisomy $21$. Conversely, there is a $100\\% - 49.77\\% = 50.23\\%$ chance that the result is a false positive. This counter-intuitive outcome, where a test with high sensitivity ($99\\%$) and specificity ($99.9\\%$) yields a positive result that is more likely to be false than true, is a classic illustration of the effect of low prevalence on predictive values (an instance of the base rate fallacy).\n\nThis calculated PPV has direct implications for counseling based on core ethical principles:\n1.  **Autonomy**: Pre-test counseling must stress that NIPT is a *screening* test, not a diagnostic one. The clinician must explain that a positive result does not confirm the diagnosis but rather indicates an increased risk. By providing the patient with an accurate understanding of what the test can and cannot do, including the concept of PPV, the clinician empowers the patient to make an autonomous and informed decision about whether to proceed with screening. Post-test counseling for a positive result must quantitatively explain the PPV (i.e., \"There is about a 50-50 chance this result is a true positive\"). This allows the patient to weigh their personal values and decide on subsequent steps, such as confirmatory diagnostic testing, without undue panic or coercion.\n2.  **Beneficence and Non-maleficence**: The principle of beneficence (acting in the patient's best interest) and non-maleficence (avoiding harm) compels the clinician to prevent the harm that could arise from misinterpreting a positive NIPT result as a definitive diagnosis. Such a misunderstanding could cause severe psychological distress and could lead to irreversible decisions, such as pregnancy termination, based on a probabilistic screening result. By clearly communicating that the PPV is only about $50\\%$, the clinician acts to prevent this harm and ensures patient well-being.\n3.  **Need for Confirmatory Diagnostic Testing**: The fact that the PPV is significantly below $1.0$ (and in this case, below $0.5$) is the quantitative justification for recommending confirmatory diagnostic testing. Tests like amniocentesis or chorionic villus sampling (CVS) provide a definitive karyotype with much higher accuracy, though they carry a small risk of procedural complications. The low PPV of the screening test makes the risk-benefit analysis of an invasive diagnostic test favorable for a patient seeking diagnostic certainty. Counseling must frame confirmatory testing as the necessary next step to resolve the uncertainty created by the positive NIPT screen before any definitive clinical conclusions are drawn or irreversible decisions are made.", "answer": "$$\n\\boxed{0.4977}\n$$", "id": "5028518"}, {"introduction": "As genomic sequencing becomes a common diagnostic tool, we can uncover vast amounts of information, not all of which relates to the original reason for testing. This exercise challenges you to master the precise terminology used to classify different types of genetic findings: primary, incidental, and secondary. Understanding these distinctions is essential for navigating the complex ethical landscape of returning genomic results and for appreciating the professional guidelines developed to manage these findings responsibly [@problem_id:5028528].", "problem": "A clinical genetics team orders whole-exome sequencing for a $25$-year-old patient with unexplained cardiomyopathy. The consent process includes an option to receive additional results beyond those relevant to the cardiomyopathy. The laboratory follows guidance from the American College of Medical Genetics and Genomics (ACMG) regarding actively searched medically actionable variants. Using foundational definitions in genomic medicine—namely, that primary diagnostic results are those directly related to the indication for testing, incidental findings are unanticipated findings that arise without an intentional search, and secondary findings are intentionally sought findings outside the indication due to established medical actionability—select the option that most accurately distinguishes incidental findings from secondary findings and correctly differentiates both from primary diagnostic results, while reflecting typical categories included in ACMG-recommended actionable findings (for example, hereditary cancer predisposition and cardiovascular disorders where interventions can reduce morbidity and mortality).\n\nWhich option is most accurate?\n\nA. Primary diagnostic results are variants explaining the patient’s presenting condition; incidental findings are unexpected variants discovered during analysis that were not actively sought; secondary findings are variants intentionally searched for from a predefined list because they are medically actionable—such as those recommended by ACMG in genes for hereditary cancer predisposition and cardiovascular disorders—and may be returned irrespective of the original indication when the patient has consented.\n\nB. Secondary findings are any unexpected variants discovered during analysis without intent, while incidental findings are the results of an intentional search for medically actionable genes; primary diagnostic results include ACMG secondary findings because they are clinically important.\n\nC. Secondary findings should never be returned in adults because they pertain solely to pediatric-onset conditions, and the ACMG list primarily comprises pharmacogenomic variants with no immediate interventions.\n\nD. Incidental findings are variants discovered only when the laboratory deliberately disables phenotype-based filters; they are mandated by law to be reported in all cases regardless of the patient’s consent or clinical context.\n\nE. Primary diagnostic results exclude variants in the disease gene if the variant is a variant of uncertain significance (VUS), whereas incidental findings should include VUS; secondary findings consist only of susceptibility variants that increase relative risk but lack any proven interventions to reduce risk.", "solution": "The problem statement is evaluated for validity.\n\n**Step 1: Extract Givens**\n-   Patient: A $25$-year-old individual.\n-   Indication for testing: Unexplained cardiomyopathy.\n-   Test: Whole-exome sequencing.\n-   Consent: Includes an option for the patient to receive additional results beyond those relevant to the primary indication.\n-   Laboratory standard: Follows American College of Medical Genetics and Genomics (ACMG) guidance for actively searching for medically actionable variants.\n-   Provided Definitions:\n    -   **Primary diagnostic results:** Results directly related to the indication for testing.\n    -   **Incidental findings:** Unanticipated findings that arise without an intentional search.\n    -   **Secondary findings:** Intentionally sought findings outside the indication due to established medical actionability.\n-   Question: Select the option that most accurately distinguishes incidental from secondary findings, differentiates both from primary results, and reflects the typical categories of ACMG-recommended actionable findings.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded. The scenario describes a standard-of-care situation in contemporary clinical genetics. The use of whole-exome sequencing, the patient's condition, the consent process, and the reference to ACMG guidelines are all accurate representations of current practice. The definitions provided for primary, incidental, and secondary findings are the standard, accepted definitions within the field of genomic medicine. The problem is well-posed, objective, and self-contained, providing sufficient information to evaluate the options based on established principles and definitions. There are no scientific or factual unsoundness, contradictions, or ambiguities.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be derived by analyzing the provided options against the established definitions.\n\n**Derivation of Solution**\nThe core of the problem lies in the precise definitions of three types of genetic findings from a large-scale test like whole-exome sequencing. Let's analyze these based on the provided and standard definitions.\n\n1.  **Primary Diagnostic Results:** These are findings that pertain to the reason the test was ordered. For this $25$-year-old patient, the indication is cardiomyopathy. Therefore, the analysis will primarily focus on genes known to be associated with cardiomyopathies. A pathogenic variant found in a gene like *MYH7*, *MYBPC3*, or *TNNT2* would be a primary diagnostic result as it could explain the patient's condition.\n\n2.  **Incidental Findings (IF):** The term \"incidental\" refers to the unintentional or serendipitous nature of the discovery. While analyzing the exome data for the cardiomyopathy genes, a bioinformatician or clinical geneticist might happen to notice a pathogenic variant in a different gene that was not part of the primary analysis plan. The key attribute is that it was **not actively or intentionally sought**. For instance, a pathogenic variant in the *CFTR* gene (associated with cystic fibrosis) might be observed by chance. Due to the high \"noise\" of such findings, especially variants of uncertain significance (VUS), reporting of true incidental findings is complex and less systematic than for secondary findings.\n\n3.  **Secondary Findings (SF):** This category was formally established by the ACMG to address a specific ethical and clinical opportunity. Given that an exome or genome is being sequenced, there is an opportunity to look for other serious, but preventable or treatable, conditions. The ACMG has curated a specific list of genes (the \"ACMG SF list\") associated with medically actionable conditions. The laboratory is recommended to **intentionally search** for pathogenic or likely pathogenic variants in these specific genes and report them to patients who have consented to receive such information. This search is performed irrespective of the primary indication for testing. For example, the lab would deliberately query the patient's exome data for pathogenic variants in *BRCA1* (hereditary cancer), *LDLR* (familial hypercholesterolemia), or *KCNQ1* (long QT syndrome), because interventions exist for these conditions.\n\nThe crucial distinction is **intent**: secondary findings are intentionally sought, whereas incidental findings are not. Both are distinct from primary findings, which relate to the original clinical question.\n\n**Option-by-Option Analysis**\n\nA. Primary diagnostic results are variants explaining the patient’s presenting condition; incidental findings are unexpected variants discovered during analysis that were not actively sought; secondary findings are variants intentionally searched for from a predefined list because they are medically actionable—such as those recommended by ACMG in genes for hereditary cancer predisposition and cardiovascular disorders—and may be returned irrespective of the original indication when the patient has consented.\n-   This option correctly defines primary results as related to the presenting condition (cardiomyopathy).\n-   It correctly defines incidental findings as not actively sought.\n-   It correctly defines secondary findings as intentionally searched for, based on a predefined list (the ACMG SF list), for medically actionable conditions. It provides accurate examples (hereditary cancer, cardiovascular disorders) and correctly notes that reporting is dependent on patient consent. This description aligns perfectly with the foundational definitions.\n-   **Verdict: Correct.**\n\nB. Secondary findings are any unexpected variants discovered during analysis without intent, while incidental findings are the results of an intentional search for medically actionable genes; primary diagnostic results include ACMG secondary findings because they are clinically important.\n-   This option incorrectly swaps the definitions of incidental and secondary findings. Secondary findings are intentional; incidental findings are unintentional.\n-   It also incorrectly states that primary results include ACMG secondary findings. By definition, secondary findings are *not* related to the primary indication for testing. While they are clinically important, they belong to a separate category.\n-   **Verdict: Incorrect.**\n\nC. Secondary findings should never be returned in adults because they pertain solely to pediatric-onset conditions, and the ACMG list primarily comprises pharmacogenomic variants with no immediate interventions.\n-   This statement contains multiple factual errors. The ACMG SF list includes many conditions with adult onset (e.g., hereditary breast and ovarian cancer, Lynch syndrome, Marfan syndrome).\n-   Furthermore, the express purpose of the ACMG SF list is to identify conditions with **immediate and significant interventions** to reduce morbidity or mortality. It is not primarily a pharmacogenomics list.\n-   **Verdict: Incorrect.**\n\nD. Incidental findings are variants discovered only when the laboratory deliberately disables phenotype-based filters; they are mandated by law to be reported in all cases regardless of the patient’s consent or clinical context.\n-   The first part is a misleading oversimplification of a complex bioinformatic process and does not represent the definition of an incidental finding.\n-   The second part is a grave error. Reporting of secondary findings is a recommendation based on professional guidelines, not a legal mandate in most jurisdictions. Critically, it is dependent on explicit patient consent. Reporting such information against a patient's wishes would be an ethical violation.\n-   **Verdict: Incorrect.**\n\nE. Primary diagnostic results exclude variants in the disease gene if the variant is a variant of uncertain significance (VUS), whereas incidental findings should include VUS; secondary findings consist only of susceptibility variants that increase relative risk but lack any proven interventions to reduce risk.\n-   This statement is incorrect on all points. Primary results do not \"exclude\" VUSs; rather, a VUS is an inconclusive result that is typically reported as such. It is a finding relevant to the primary question, albeit an uninformative one.\n-   Clinical practice guidelines strongly advise *against* reporting incidental VUSs due to the potential for patient harm (anxiety, unnecessary procedures) with no clear clinical benefit.\n-   The statement about secondary findings is the direct opposite of the truth. The ACMG SF list is predicated on **high medical actionability** and proven interventions; it deliberately excludes low-penetrance susceptibility variants for which clear risk-reduction strategies are not available.\n-   **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "5028528"}, {"introduction": "The power of genetic information brings with it valid concerns about potential misuse and discrimination. This practice requires you to analyze the key legal protections for genetic information in the United States, specifically how the Genetic Information Nondiscrimination Act (GINA) works alongside the Americans with Disabilities Act (ADA) and the Affordable Care Act (ACA). Correctly differentiating these laws and their specific applications is critical for advising patients on their rights regarding employment and health insurance, particularly in distinguishing between protections for genetic risk versus a manifested disease [@problem_id:5028553].", "problem": "An advanced genomics clinic is training counselors to advise clients on legal protections surrounding genetic information and disease. The training emphasizes reasoning from statutory purpose and core definitions in United States law: that Genetic Information Nondiscrimination Act (GINA) regulates the use of genetic information, the Americans with Disabilities Act (ADA) regulates discrimination based on disability in employment, and the Affordable Care Act (ACA) regulates health insurance practices including preexisting condition exclusions and health status underwriting. Counselors must distinguish protections that attach to genetic risk (e.g., an asymptomatic pathogenic variant) versus protections that attach to manifest disease (e.g., a current diagnosis with symptoms), and understand sector-specific scope (employment versus health insurance versus life insurance).\n\nYou are asked to evaluate the following statements for correctness. Your task is to select all statements that accurately contrast the protections offered by GINA with those under the ADA and the ACA, and that correctly describe their distinct applicability to genetic risk versus manifest disease.\n\nA. In employment, GINA’s nondiscrimination provisions apply to genetic information such as genetic test results and family history, but discrimination based solely on a current diagnosis is not “genetic information”; when a genetic condition is manifested, the ADA, rather than GINA, is the principal law prohibiting discrimination and requiring reasonable accommodation if the impairment substantially limits a major life activity.\n\nB. For health insurance, the ACA bars denying coverage, imposing preexisting condition exclusions, or health-status underwriting for both genetic risk and manifest disease; by contrast, GINA’s health insurance provisions specifically prohibit requesting or using genetic information for underwriting and eligibility, but by themselves do not address underwriting based on a current diagnosis.\n\nC. GINA prohibits life, disability, and long-term care insurers from requesting or using genetic test results, so consumers with pathogenic variants but no symptoms are protected across those markets.\n\nD. The ADA protects asymptomatic carriers of pathogenic variants because they are “regarded as” disabled and therefore obligates employers to provide reasonable accommodations to prevent potential future impairment even in the absence of current limitation.\n\nE. The ACA allows health insurers to collect genetic information for underwriting as long as they do not deny coverage on that basis; GINA, by contrast, prohibits collection of genetic information for underwriting but permits its use if voluntarily provided by the applicant.\n\nF. ADA protections apply only to employers with at least $15$ employees, whereas GINA’s employment provisions apply to all employers regardless of size.\n\nSelect all that apply.", "solution": "The problem asks for an evaluation of several statements describing the legal protections afforded by the Genetic Information Nondiscrimination Act (GINA), the Americans with Disabilities Act (ADA), and the Affordable Care Act (ACA) in the United States, specifically concerning the distinction between genetic risk and manifest disease in different sectors. The problem statement is valid as it is grounded in established legal and scientific principles, is well-posed, objective, and requires a nuanced understanding of real-world statutes.\n\nWe will proceed with a detailed analysis of each option.\n\nA. **In employment, GINA’s nondiscrimination provisions apply to genetic information such as genetic test results and family history, but discrimination based solely on a current diagnosis is not “genetic information”; when a genetic condition is manifested, the ADA, rather than GINA, is the principal law prohibiting discrimination and requiring reasonable accommodation if the impairment substantially limits a major life activity.**\n\nThis statement accurately delineates the respective domains of GINA and the ADA in the employment context.\n- **GINA's Scope in Employment:** Title II of GINA prohibits employers from discriminating against employees or applicants based on their \"genetic information.\" The law defines \"genetic information\" to include an individual's genetic tests, the genetic tests of family members, and the manifestation of a disease or disorder in family members (i.e., family medical history).\n- **GINA's Manifest Disease Exclusion:** A crucial element of GINA is that it explicitly excludes a manifested disease or disorder from the definition of \"genetic information.\" Therefore, if an employer discriminates against an individual because they are currently sick, that action is not prohibited by GINA, even if the sickness has a genetic basis.\n- **ADA's Role:** The ADA prohibits discrimination on the basis of \"disability.\" A manifested genetic condition that substantially limits one or more major life activities qualifies as a disability under the ADA. Thus, the ADA provides protection where GINA's protection ends. The ADA also mandates that employers provide \"reasonable accommodations\" for qualified individuals with disabilities, a provision not found in GINA.\nThis statement correctly captures this critical hand-off from GINA (protecting against discrimination based on future risk) to the ADA (protecting against discrimination based on current disability).\n\nVerdict: **Correct**.\n\nB. **For health insurance, the ACA bars denying coverage, imposing preexisting condition exclusions, or health-status underwriting for both genetic risk and manifest disease; by contrast, GINA’s health insurance provisions specifically prohibit requesting or using genetic information for underwriting and eligibility, but by themselves do not address underwriting based on a current diagnosis.**\n\nThis statement correctly contrasts the protections of the ACA and GINA in the health insurance market.\n- **ACA's Protections:** The ACA instituted broad reforms, most notably prohibiting health insurers in the individual and group markets from denying coverage, charging higher premiums, or imposing preexisting condition exclusions based on an individual's health status. \"Health status\" is a wide-ranging term that encompasses both manifest diseases (current conditions) and genetic predispositions to disease (genetic risk).\n- **GINA's Protections in Health Insurance:** Title I of GINA is more specific. It prohibits group and individual health insurers from using an individual's genetic information to make underwriting decisions (e.g., setting premiums) or for eligibility determinations. It also prohibits them from requesting or requiring an individual to undergo a genetic test. Like its employment provisions, GINA's health insurance protections do not apply to a manifested disease.\nThe statement accurately portrays the ACA as providing a broad protective floor for all health conditions (risk and manifest disease), while GINA provides targeted, and in some ways more stringent, protections specifically for genetic information (e.g., a prohibition on even requesting the information for underwriting purposes), while not covering discrimination based on a current diagnosis.\n\nVerdict: **Correct**.\n\nC. **GINA prohibits life, disability, and long-term care insurers from requesting or using genetic test results, so consumers with pathogenic variants but no symptoms are protected across those markets.**\n\nThis statement is factually incorrect. GINA's provisions apply only to health insurance (Title I) and employment (Title II). The law explicitly does not extend to other forms of insurance, such as life insurance, disability insurance, or long-term care insurance. Insurers in these markets are generally permitted under federal law to request and use genetic information, including genetic test results, in their underwriting processes. This is a widely recognized limitation of GINA.\n\nVerdict: **Incorrect**.\n\nD. **The ADA protects asymptomatic carriers of pathogenic variants because they are “regarded as” disabled and therefore obligates employers to provide reasonable accommodations to prevent potential future impairment even in the absence of current limitation.**\n\nThis statement contains a critical legal error. The ADA defines disability in three ways: (1) a physical or mental impairment that substantially limits one or more major life activities (an \"actual\" disability); (2) a record of such an impairment; or (3) being \"regarded as\" having such an impairment. While an asymptomatic carrier might be protected under the \"regarded as\" prong if their employer mistakenly believes their genetic status is a current, limiting impairment, the law is explicit on the matter of accommodations. The ADA Amendments Act of 2008 (ADAAA) clarifies that an employer is **not** required to provide a reasonable accommodation to an individual who meets only the \"regarded as\" definition of disability. The obligation to provide reasonable accommodation applies only to individuals with an actual disability or a record of one. The statement's claim that \"regarded as\" status obligates an employer to provide accommodations is a direct contradiction of the statute.\n\nVerdict: **Incorrect**.\n\nE. **The ACA allows health insurers to collect genetic information for underwriting as long as they do not deny coverage on that basis; GINA, by contrast, prohibits collection of genetic information for underwriting but permits its use if voluntarily provided by the applicant.**\n\nThis statement misrepresents both the ACA and GINA.\n- **ACA:** The ACA prohibits health-status underwriting in most markets. While it may not have an explicit \"thou shalt not collect\" provision like GINA, its ban on the *use* of such information for underwriting effectively renders its collection for that purpose prohibited. The premise that the ACA \"allows\" this collection for underwriting is misleading and functionally incorrect.\n- **GINA:** GINA prohibits health insurers from *using* genetic information for underwriting purposes, regardless of whether it was requested or provided voluntarily. If an insurer comes into possession of genetic information (e.g., it is included in a medical record provided by the applicant), the insurer is still barred from using it to set premiums or determine eligibility. The statement's claim that GINA \"permits its use if voluntarily provided\" is false.\n\nVerdict: **Incorrect**.\n\nF. **ADA protections apply only to employers with at least $15$ employees, whereas GINA’s employment provisions apply to all employers regardless of size.**\n\nThis statement incorrectly describes the scope of GINA. Title I of the ADA, which covers employment, applies to employers with $15$ or more employees. Title II of GINA, which covers employment, was designed to be consistent with the scope of other federal anti-discrimination laws, including the ADA. Therefore, GINA's employment provisions also apply only to employers with $15$ or more employees. The statement's claim that GINA applies to all employers regardless of size is false.\n\nVerdict: **Incorrect**.", "answer": "$$\\boxed{AB}$$", "id": "5028553"}]}